a Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital , Shenzhen , China.
b Special Pathogens Program, National Microbiology Laboratory , Winnipeg , Canada.
Hum Vaccin Immunother. 2018 Jul 3;14(7):1760-1762. doi: 10.1080/21645515.2017.1412024. Epub 2018 Jan 16.
Immunization has played a large role in substantially reducing the infected and death tolls from infectious diseases. In the case of emerging diseases, the identity of the pathogen responsible, as well as the time and location for the next outbreak, cannot be accurately predicted using current means. Coupled with disjointed efforts towards the development of vaccines and a lack of funds and desire to advance promising products against known emerging pathogens to clinical trials, there has been a shortage of approved products ready for emergency use. Recent outbreaks have exposed these weaknesses, and the Coalition for Epidemic Preparedness Innovations (CEPI) was created in 2016 to address these issues. In this commentary, we discuss the establishment of such a global vaccine fund, and provide some additional points to consider for stimulating further discussion on this comprehensive, ambitious initiative.
免疫接种在大幅降低传染病感染和死亡人数方面发挥了重要作用。对于新出现的疾病,目前的手段无法准确预测病原体的身份以及下一次爆发的时间和地点。此外,疫苗的开发工作也缺乏协调,资金和推进针对已知新兴病原体的有前途产品进入临床试验的意愿也不足,因此,没有经过批准可用于紧急使用的产品。最近的疫情爆发暴露了这些弱点,为此,流行病防范创新联盟(CEPI)于 2016 年成立,以应对这些问题。在本篇评论中,我们讨论了建立这样一个全球疫苗基金的问题,并提出了一些其他需要考虑的观点,以进一步讨论这一全面而雄心勃勃的倡议。